Presenter: Dr. Pieter Kennis | Associate Scientist High Throughput Profiling Unit | Ablynx, a Sanofi Company
In this webinar, Dr. Pieter Kennis discusses how nanobodies – small, single-domain antibody fragments that retain full antigen-binding capabilities and the properties of heavy-chain antibodies – and nanobody discovery and screening platforms exploit high-throughput flow cytometry to increase the throughput of nanobody screening campaigns.
Join Dr. Pieter Kennis to learn about:
- Efficient labeling of multiple cell lines for simultaneous analysis
- Multiplexed nanobody screening, assay setup and analysis to screen for compound binding (with examples from nanobody discovery campaigns)
- Nanobody characterization – semi-automated data analysis to determine EC50 values from dose response binding.
While antibodies are set to be increasingly important as therapeutic options for cancer and other diseases, the discovery of fully functional antibodies that lack light chains in Camelidae (camels and llamas) has opened the door to an exciting new generation of therapeutic antibodies known as nanobodies.
Unlike conventional antibodies, the heavy-chain antibodies of Camelidae contain a single variable domain (VHH) and two constant domains (CH2 and CH3) only. Using these functional antibodies as a base, nanobodies have been created and represent the next generation in antibody-derived biologics.
Learn more about Sartorius solutions for mAb Discovery & Development at www.sartorius.com/mab-oncology.